283 related articles for article (PubMed ID: 27056729)
1. A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease.
Wilson JC; Furlano RI; Jick SS; Meier CR
J Gastroenterol; 2016 Nov; 51(11):1050-1062. PubMed ID: 27056729
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory Bowel Disease and the Risk of Autoimmune Diseases.
Wilson JC; Furlano RI; Jick SS; Meier CR
J Crohns Colitis; 2016 Feb; 10(2):186-93. PubMed ID: 26507860
[TBL] [Abstract][Full Text] [Related]
3. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications.
Ban L; Tata LJ; Fiaschi L; Card T
Gastroenterology; 2014 Jan; 146(1):76-84. PubMed ID: 24126096
[TBL] [Abstract][Full Text] [Related]
4. Incidence, management, and course of cancer in patients with inflammatory bowel disease.
Algaba A; Guerra I; Marín-Jiménez I; Quintanilla E; López-Serrano P; García-Sánchez MC; Casis B; Taxonera C; Moral I; Chaparro M; Martín-Rodríguez D; Martín-Arranz MD; Manceñido N; Menchén L; López-Sanromán A; Castaño Á; Bermejo F
J Crohns Colitis; 2015 Apr; 9(4):326-33. PubMed ID: 25687203
[TBL] [Abstract][Full Text] [Related]
5. Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.
Khan N; Vallarino C; Lissoos T; Darr U; Luo M
Drugs Aging; 2017 Nov; 34(11):859-868. PubMed ID: 29170864
[TBL] [Abstract][Full Text] [Related]
6. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study.
Armstrong RG; West J; Card TR
Am J Gastroenterol; 2010 Jul; 105(7):1604-9. PubMed ID: 20104215
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study.
Biancone L; Armuzzi A; Scribano ML; D'Inca R; Castiglione F; Papi C; Angelucci E; Daperno M; Mocciaro F; Riegler G; Fries W; Meucci G; Alvisi P; Spina L; Ardizzone S; Petruzziello C; Ruffa A; Kohn A; Vecchi M; Guidi L; Di Mitri R; Renna S; Emma C; Rogai F; Rossi A; Orlando A; Pallone F;
J Crohns Colitis; 2016 Aug; 10(8):913-24. PubMed ID: 26933032
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease.
Singh H; Nugent Z; Demers AA; Bernstein CN
Gastroenterology; 2011 Nov; 141(5):1612-20. PubMed ID: 21806945
[TBL] [Abstract][Full Text] [Related]
9. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study.
Rungoe C; Basit S; Ranthe MF; Wohlfahrt J; Langholz E; Jess T
Gut; 2013 May; 62(5):689-94. PubMed ID: 22961677
[TBL] [Abstract][Full Text] [Related]
10. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
Bernstein CN; Blanchard JF; Metge C; Yogendran M
Am J Gastroenterol; 2003 Dec; 98(12):2784-8. PubMed ID: 14687833
[TBL] [Abstract][Full Text] [Related]
11. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
Carrat F; Seksik P; Colombel JF; Peyrin-Biroulet L; Beaugerie L;
Aliment Pharmacol Ther; 2017 Feb; 45(4):533-541. PubMed ID: 27995656
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study.
Rungoe C; Simonsen J; Riis L; Frisch M; Langholz E; Jess T
Clin Gastroenterol Hepatol; 2015 Apr; 13(4):693-700.e1. PubMed ID: 25086189
[TBL] [Abstract][Full Text] [Related]
13. Screening differences and risk of cervical cancer in inflammatory bowel disease.
Hutfless S; Fireman B; Kane S; Herrinton LJ
Aliment Pharmacol Ther; 2008 Sep; 28(5):598-605. PubMed ID: 18549465
[TBL] [Abstract][Full Text] [Related]
14. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study.
Baars JE; Looman CW; Steyerberg EW; Beukers R; Tan AC; Weusten BL; Kuipers EJ; van der Woude CJ
Am J Gastroenterol; 2011 Feb; 106(2):319-28. PubMed ID: 21045815
[TBL] [Abstract][Full Text] [Related]
15. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
16. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.
Van Staa TP; Travis S; Leufkens HG; Logan RF
Gastroenterology; 2004 Jun; 126(7):1733-9. PubMed ID: 15188168
[TBL] [Abstract][Full Text] [Related]
17. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).
Magro F; Peyrin-Biroulet L; Sokol H; Aldeger X; Costa A; Higgins PD; Joyce JC; Katsanos KH; Lopez A; de Xaxars TM; Toader E; Beaugerie L
J Crohns Colitis; 2014 Jan; 8(1):31-44. PubMed ID: 23721759
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients.
Sridhar AR; Parasa S; Navaneethan U; Crowell MD; Olden K
J Crohns Colitis; 2011 Aug; 5(4):287-94. PubMed ID: 21683298
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota.
Jess T; Loftus EV; Velayos FS; Winther KV; Tremaine WJ; Zinsmeister AR; Scott Harmsen W; Langholz E; Binder V; Munkholm P; Sandborn WJ
Am J Gastroenterol; 2007 Apr; 102(4):829-36. PubMed ID: 17222314
[TBL] [Abstract][Full Text] [Related]
20. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
